SCHEMBL3890971

SCHEMBL3890971

C=CCSc1ccc(OC)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.52
ALDH1A1 P00352 4/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
CYP3A4 P08684 1/20 0.52
ALOX15 P16050 1/20 0.52
TSHR P16473 1/20 0.52
ALOX12 P18054 1/20 0.52
NPC1 O15118 3/20 0.51
RAB9A P51151 2/20 0.51
HPGD P15428 1/20 0.51
APP P05067 1/20 0.47
CYP1A1 P04798 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP1B1 Q16678 1/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8755108 0.82 L3MBTL1 (0.41) ALDH1A1SMN1; SMN2CYP3A4ALOX15HPGD
SCHEMBL19786023 0.82 ALDH1A1 (0.40) TP53ALDH1A1SMN1; SMN2CYP3A4ALOX15
SCHEMBL19786083 0.82 ALDH1A1 (0.40) TP53ALDH1A1SMN1; SMN2CYP3A4ALOX15
SCHEMBL10903718 0.81 APP (0.45) TP53ALDH1A1SMN1; SMN2CYP3A4ALOX15
SCHEMBL11881040 0.81 NQO1 (0.52) TP53ALDH1A1SMN1; SMN2TSHRNPC1
SCHEMBL1951997 0.80 MTNR1A (0.47) TP53ALDH1A1NPC1RAB9AAPP
SCHEMBL12717349 0.79 TEAD4 (0.42) TP53ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL7154447 0.78 L3MBTL1 (0.38) ALDH1A1SMN1; SMN2CYP3A4ALOX15HPGD
SCHEMBL21191983 0.78 MTNR1A (0.49) TP53ALDH1A1SMN1; SMN2CYP3A4NPC1
SCHEMBL314128 0.77 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2CYP3A4TSHRRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019143142-A1 NOVEL PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING GLIOBLASTOMA 숙명여자대학교 산학협력단 2019-07-25 WO disclosed
EP-3178811-A1 A PROCESS FOR THE SYNTHESIS OF SULFONES AND SULFONAMIDES COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES (FR) 2017-06-14 EP disclosed
US-20090264660-A1 PROCESS FOR ALKYL ARYL SULFIDE DERIVATIVES AND NEW SULFIDE COMPOUNDS Kang, Heonjoong (KR) 2009-10-22 US disclosed
US-20090264660-A1 PROCESS FOR ALKYL ARYL SULFIDE DERIVATIVES AND NEW SULFIDE COMPOUNDS Kang, Heonjoong (KR) 2009-10-22 US disclosed
US-20090264660-A1 PROCESS FOR ALKYL ARYL SULFIDE DERIVATIVES AND NEW SULFIDE COMPOUNDS Kang, Heonjoong (KR) 2009-10-22 US disclosed
EP-0410379-B1 Pharmaceutically active 3-aryl and 3-heteroaryl-2-fluoro-1-olefins MERRELL DOW PHARMA (US) 1996-01-31 EP disclosed
US-5068465-A Hypotensive agents or enzyme inhibitors for treatment of hypertension MERRELL DOW PHARMACEUTICALS INC. (US) 1991-11-26 US disclosed
EP-0410379-A2 Pharmaceutically active 3-aryl and 3-heteroaryl-2-fluoro-1-olefins MERRELL DOW PHARMACEUTICALS INC. (US) 1991-01-30 EP disclosed
US-4981868-A ENZYME INHIBITORS, HYPOTENSIVES MERRELL DOW PHARMACEUTICAL (US) 1991-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264660-A1 PROCESS FOR ALKYL ARYL SULFIDE DERIVATIVES AND NEW SULFIDE COMPOUNDS TST, ARSA, STS TP53 4696/4885ALDH1A1 210/4885SMN1; SMN2 2917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.